[1] Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579(7798):265 − 9. http://dx.doi.org/10.1038/s41586-020-2008-3CrossRef
[2] Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579(7798):270 − 3. http://dx.doi.org/10.1038/s41586-020-2012-7CrossRef
[3] Zhu N, Zhang DY, Wang WL, Li XW, Yang B, Song JD, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727 − 33. http://dx.doi.org/10.1056/NEJMoa2001017CrossRef
[4] Li Q, Guan XH, Wu P, Wang XY, Zhou L, Tong YQ, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020;382(13):1199 − 207. http://dx.doi.org/10.1056/NEJMoa2001316CrossRef
[5] World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. [2021-9-4].https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
[6] World Health Organization. WHO coronavirus (COVID-19) dashboard. 2021. https://covid19.who.int/. [2021-9-4].https://covid19.who.int/
[7] Lauring AS, Hodcroft EB. Genetic variants of SARS-CoV-2-what do they mean? JAMA 2021;325(6):529 − 31. http://dx.doi.org/10.1001/jama.2020.27124CrossRef
[8] World Health Organization. Tracking SARS-CoV-2 variants. 2021. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/. [2021-9-22].https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
[9] Wang FZ, An ZJ, Rodewald L, Wu D, Tang L, Zheng H, et al. Guangdong’s study of the effectiveness of China’s inactivated vaccines against the SARS-CoV-2 B. 1. 617. 2 (Delta) variant. China CDC Wkly 2021;3(34):728 − 30. http://dx.doi.org/10.46234/ccdcw2021.179CrossRef
[10] Chadha J, Khullar L, Mittal N. Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease-19 pandemic. Environ Microbiol 2021. http://dx. doi.org/10.1111/1462-2920.15687.http://dx. doi.org/10.1111/1462-2920.15687
[11] REGENERON. COVID-19 dashboard. 2021. https://covid19dashboard.regeneron.com/?tab=Variant_Graphs&subTab=Top_Variants_Over_Time_(Select_Location). [2021-8-24].https://covid19dashboard.regeneron.com/?tab=Variant_Graphs&subTab=Top_Variants_Over_Time_(Select_Location)
[12] World Health Organization. WHO recommendation COVID-19 vaccine BIBP/sinopharm. 2021. https://extranet.who.int/pqweb/vaccines/who-recommendation-covid-19-vaccine-bibp. [2021-9-4].https://extranet.who.int/pqweb/vaccines/who-recommendation-covid-19-vaccine-bibp
[13] World Health Organization. Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process. 2021. https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_20Jan2021.pdf.https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_20Jan2021.pdf
[14] Our World in Data. Coronavirus (COVID-19) vaccinations. 2021. https://ourworldindata.org/covid-vaccinations. [2021-9-22].https://ourworldindata.org/covid-vaccinations
[15] Melnick ER, Ioannidis JPA. Should governments continue lockdown to slow the spread of covid-19? BMJ 2020;369:m1924. http://dx.doi.org/10.1136/bmj.m1924CrossRef
[16] Li C, Zhong Y, Wu Y, Yang CH, Zhou LJ,Zhang T. Research and prospect of non-pharmaceutical interventions in COVID-19. Mod Prev Med 2021;48(3):385 − 8.
[17] Shi QF, Gao XD, Hu BJ. Research progress on characteristics, epidemiology and control measure of SARS-CoV-2 Delta VOC. Chin J Nosocomiol 2021. http://kns.cnki.net/kcms/detail/11.3456.R.20210707.2126.070.html. [2021-9-16]. (In Chinese). http://kns.cnki.net/kcms/detail/11.3456.R.20210707.2126.070.html
[18] Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2021. https://pubmed.ncbi.nlm.nih.gov/32150360/.https://pubmed.ncbi.nlm.nih.gov/32150360/
[19] Zhao X, Zheng AQ, Li DD, Zhang R, Sun H, Wang QH, et al. Neutralization of recombinant RBD-subunit vaccine ZF2001-elicited antisera to SARS-CoV-2 variants including Delta. bioRxiv 2021. http://dx. doi.org/10.1101/2021.07.15.452504.http://dx. doi.org/10.1101/2021.07.15.452504
[20] Khateeb J, Li YC, Zhang HB. Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Crit Care 2021;25(1):244. http://dx.doi.org/10.1186/s13054-021-03662-xCrossRef
[21] Feng YN, Song Y, Wang SW, Chen C, Xu WB. Research advances in global SARS-CoV-2 variants. Chin J Virol 2021;37(3):17. (In Chinese). 
[22] Pango Network. New AY lineages. 2021. https://www.pango.network/new-ay-lineages/. [2021-9-14].https://www.pango.network/new-ay-lineages/
[23] Kannan SR, Spratt AN, Cohen AR, Naqvi SH, Chand HS, Quinn TP, et al. Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses. J Autoimmun 2021;124:102715. http://dx.doi.org/10.1016/j.jaut.2021.102715CrossRef
[24] Callaway E. Delta coronavirus variant: scientists brace for impact. Nature 2021;595(7865):17 − 8. http://dx.doi.org/10.1038/d41586-021-01696-3CrossRef
[25] Bolze A, Cirulli ET, Luo SS, White S, Wyman D, Dei Rossi A, et al. SARS-CoV-2 variant Delta rapidly displaced variant Alpha in the United States and led to higher viral loads. medRxiv 2021. http://dx. doi.org/10.1101/2021.06.20.21259195.http://dx. doi.org/10.1101/2021.06.20.21259195
[26] Zhuo JT. The strategy to overcome attack with an ultra-short incubation period and escape with an ultra-long incubation period of the COVID-19 Delta variant of based on cases of outbreaks and their containment. Shanghai J Prev Med 2021. http://kns.cnki.net/kcms/detail/31.1635.R.20210729.1041.002.html. [2021-9-16]. (In Chinese). http://kns.cnki.net/kcms/detail/31.1635.R.20210729.1041.002.html
[27] Tang S, Mao YX, Jones RM, Tan QY, Ji JS, Li N, et al. Aerosol transmission of SARS-CoV-2? Evidence, prevention and control. Environ Int 2020;144:106039. http://dx.doi.org/10.1016/j.envint.2020.106039CrossRef
[28] Jones RM, Brosseau LM. Aerosol transmission of infectious disease. J Occup Environ Med 2015;57(5):501 − 8. http://dx.doi.org/10.1097/JOM.0000000000000448CrossRef
[29] Brlek A, Vidovič Š, Vuzem S, Turk K, Simonović Z. Possible indirect transmission of COVID-19 at a squash court, Slovenia, March 2020: case report. Epidemiol Infect 2020;148:e120. http://dx.doi.org/10.1017/S0950268820001326CrossRef
[30] Cai J, Sun WJ, Huang JP, Gamber M, Wu J, He GQ. Indirect virus transmission in cluster of COVID-19 cases, Wenzhou, China, 2020. Emerg Infect Dis 2020;26(6):1343 − 5. http://dx.doi.org/10.3201/eid2606.200412CrossRef
[31] Miller SL, Nazaroff WW, Jimenez JL, Boerstra A, Buonanno G, Dancer SJ, et al. Transmission of SARS-CoV-2 by inhalation of respiratory aerosol in the Skagit Valley Chorale superspreading event. Indoor Air 2021;31(2):314 − 23. http://dx.doi.org/10.1111/ina.12751CrossRef
[32] Zhang ZN, Li X, Wang Q, Xu J, Jiang QQ, Jiang SL, et al. Field simulation of aerosol transmission of SARS-CoV-2 in a special building layout — Guangdong province, China, 2021. China CDC Wkly 2021;3(34):711 − 5. http://dx.doi.org/10.46234/ccdcw2021.176CrossRef
[33] Lustig Y, Zuckerman N, Nemet I, Atari N, Kliker L, Regev-Yochay G, et al. Neutralising capacity against Delta (B. 1. 617. 2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel. Eurosurveillance 2021;26(26):pii=2100557. http://dx.doi.org/10.2807/1560-7917.ES.2021.26.26.2100557CrossRef
[34] Chia PY, Ong SWX, Chiew CJ, Ang LW, Chavatte JM, Mak TM, et al. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. medRxiv 2021. http://dx. doi.org/10.1101/2021.07.28.21261295.http://dx. doi.org/10.1101/2021.07.28.21261295
[35] Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang BB, Tuekprakhon A, et al. Reduced neutralization of SARS-CoV-2 B. 1. 617 by vaccine and convalescent serum. Cell 2021;184(16):4220 − 36.e13. http://dx.doi.org/10.1016/j.cell.2021.06.020CrossRef
[36] Farinholt T, Doddapaneni H, Qin X, Menon V, Meng QC, Metcalf G, et al. Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections. medRxiv 2021. http://dx.doi.org/10.1101/2021.06.28.21258780.http://dx.doi.org/10.1101/2021.06.28.21258780
[37] Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K, et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B. 1. 617. 2 (Delta) variant predominance - eight U. S. locations, December 2020(34):1167 − 9. http://dx.doi.org/10.15585/mmwr.mm7034e4CrossRef
[38] Nanduri S, Pilishvili T, Derado G, Soe MM, Dollard P, Wu H, et al. Effectiveness of pfizer-BioNTech and moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B. 1. 617. 2 (Delta) variant - national healthcare safety network, March 1-August 1, 2021(34):1163 − 6. http://dx.doi.org/10.15585/mmwr.mm7034e3CrossRef
[39] Coronavirus (COVID-19) Deaths- Statistics and Research - Our World in Data[EB/OL]. [2021/9/21]. https://ourworldindata.org/covid-deaths.https://ourworldindata.org/covid-deaths
[40] Bose P. Scientists suspect Lambda SARS-CoV-2 variant most dangerous. News-Medical. 2021. https://www.news-medical.net/news/20210730/Scientists-suspect-Lambda-SARS-CoV-2-variant-most-dangerous.aspx. [2021-9-16].https://www.news-medical.net/news/20210730/Scientists-suspect-Lambda-SARS-CoV-2-variant-most-dangerous.aspx.
[41] Kimura I, Kosugi Y, Wu JQ, Yamasoba D, Butlertanaka EP, Tanaka YL, et al. SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance. bioRxiv 2021. http://dx.doi.org/10.1101/2021.07.28.454085.http://dx.doi.org/10.1101/2021.07.28.454085
[42] Sina Finance. Variants of the SARS-CoV-2 viruses emerge in endlessly, and “Lamda” appears after “Delta”. 2021. https://baijiahao.baidu.com/s?id=1707407314247784486&wfr=spider&for=pc. [2021-8-19]. (In Chinese). https://baijiahao.baidu.com/s?id=1707407314247784486&wfr=spider&for=pc
[43] Tada T, Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR. SARS-CoV-2 lambda variant remains susceptible to neutralization by mRNA vaccine-elicited antibodies and convalescent serum. bioRxiv 2021. http://dx. doi.org/10.1101/2021.07.02.450959. http://dx. doi.org/10.1101/2021.07.02.450959
[44] Acevedo ML, Alonso-Palomares L, Bustamante A, Gaggero A, Paredes F, Cortés CP, et al. Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda. medRxiv 2021. http://dx.doi.org/10.1101/2021.06.28.21259673. http://dx.doi.org/10.1101/2021.06.28.21259673
[45] National Health Commission of the People’s Republic of China. Notice on issuing the normalization of prevention and control guidelines f COVID-19 (August 2021) for focus populations in focus units and units. 2021. http://www.nhc.gov.cn/xcs/zhengcwj/202108/ead4082ee97b49a38a8512e112f53dbf.shtml. [2021-9-4]. (In Chinese). http://www.nhc.gov.cn/xcs/zhengcwj/202108/ead4082ee97b49a38a8512e112f53dbf.shtml
[46] World Health Organization. Weekly epidemiological update on COVID-19 - 31 August 2021. 2021. http://www.gov.cn/xinwen/2020-04/09/content_5500689.htm. [2021-9-6].http://www.gov.cn/xinwen/2020-04/09/content_5500689.htm
[47] National Health Commission of the People’s Republic of China. Notice on issuing the guidelines for the public and focus occupational groups to wear masks (August 2021 Edition). 2021. http://www.gov.cn/xinwen/2021-08/13/content_5631097.htm. [2021-9-4]. (In Chinese). http://www.gov.cn/xinwen/2021-08/13/content_5631097.htm
[48] National Health Commission of the People’s Republic of China. Notice on issuing the protocol for prevention and control of COVID-19 (Edition 8). 2021. http://www.gov.cn/xinwen/2021-05/14/content_5606469.htm. [2021-9-4]. (In Chinese). http://www.gov.cn/xinwen/2021-05/14/content_5606469.htm
[49] Yang TH, Zhang XY, Xu JQ. SARS-CoV-2 vaccines: current situation and prospect. Chin J Infect Control 2021;20(7): 673−80. http://www.zggrkz.com/CN/abstract/abstract30922.shtml. (In Chinese). http://www.zggrkz.com/CN/abstract/abstract30922.shtml